Clearside Biomedical Faces 41% Stock Decline Amid Key Developments in Suprachoroidal Therapies
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Clearside Biomedical, Inc. (NASDAQ: CLSD) is a biopharmaceutical company specializing in targeted drug delivery to the back of the eye through its patented suprachoroidal space (SCS®) injection platform. As of July 17, 2025, the company’s shares closed at USD 0.4899, reflecting a decline of 41.40% on a trading volume of 1,306,406 shares.
| Ticker | Exchange | Price (USD) | Change (%) | Volume |
|---|---|---|---|---|
| CLSD | NASDAQ | 0.4899 | –41.40 | 1,306,406 |
Corporate Structure
Headquartered in Alpharetta, Georgia, Clearside employs teams across research and development, regulatory affairs, clinical operations, and commercial functions. The executive leadership includes President and CEO George Lasezkay, Pharm.D., J.D., and Victor Chong, M.D., MBA, serving as Chief Medical Officer and EVP, Head of R&D. Clearside’s strategic alliances include Bausch + Lomb for the commercialization of XIPERE® (triamcinolone acetonide injectable suspension) and partnerships with REGENXBIO, Aura Biosciences, and Arctic Vision for clinical development outside the U.S.
SCS Microinjector by National Cancer Institute
Recent Developments and News
- May 15, 2025: Clearside filed a Form S-8 registration statement to offer equity awards under its 2016 Equity Incentive Plan, aimed at retaining and motivating employees across its global operations.
- May 30, 2025: A Form 8-K disclosed amendments to corporate governance documents and reported the outcomes of shareholder actions.
- June 17, 2025: In a press release via GlobeNewswire, Clearside announced that its SCS Microinjector platform would be featured in three presentations at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las Vegas. Presentations include updates on:
- Suprachoroidal CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration, in collaboration with REGENXBIO.
- One-time suprachoroidal ABBV-RGX-314 for diabetic retinopathy, in partnership with Aura Biosciences.
- The global Phase 3 CoMpass trial of Bel-sar in choroidal melanoma.
- July 17, 2025: A Form 8-K filing covered changes in executive appointments (Item 5.02), material agreements (Item 2.05), adoption of new accounting standards (Item 8.01), and other corporate updates (Item 9.01).
- LinkedIn Coverage: Modern Retina and Dilraj Grewal, M.D., FASRS, highlighted the SCS Microinjector as the only FDA-approved method to access the suprachoroidal space, emphasizing its clinical application when delivering triamcinolone acetonide.
Financial and Strategic Analysis
Clearside’s stock price decline of 41.40% on July 17, 2025, follows a period of increased R&D spending and equity dilution. The impending Phase 3 data readout for CLS-AX and ongoing regulatory interactions represent potential catalysts for the company. Commercialization of XIPERE by Bausch + Lomb provides a revenue stream, primarily through royalty-based income. Partnerships with REGENXBIO and Aura Biosciences may help distribute development risk and expenses across multiple retinal indications. Continued funding will be necessary to advance the pipeline, making future equity offerings or collaborations plausible.
Market Position and Industry Context
The global retinal therapeutics market includes intravitreal anti-VEGF injections such as ranibizumab and aflibercept. Clearside’s SCS Microinjector offers a compartmentalized delivery approach, establishing the company in the niche of suprachoroidal administration. With over 10,000 injections performed to date, Clearside has accumulated clinical and regulatory experience. Competitors focusing on sustained-release implants and gene therapies are pursuing similar objectives regarding long-term treatment efficacy; however, Clearside’s non-surgical, in-office procedure presents a distinct approach.
tl;dr
On June 21, 2025, Clearside will present Phase 3 program updates for its suprachoroidal therapies at CTS in Las Vegas. The company’s share price fell 41.40% to USD 0.4899 on July 17, 2025, amid continued R&D investment and equity dilution. Upcoming catalysts include the CLS-AX Phase 3 data readout, potential new partnerships, and ongoing commercialization milestones for XIPERE.